S
42.76
-0.04 (-0.09%)
| Previous Close | 42.80 |
| Open | 42.33 |
| Volume | 1,174,461 |
| Avg. Volume (3M) | 2,122,566 |
| Market Cap | 4,361,838,592 |
| Price / Sales | 13.14 |
| Price / Book | 18.40 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
AIStockmoo Score
-1.0
| Analyst Consensus | 4.0 |
| Insider Activity | -2.5 |
| Price Volatility | -3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.00 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (UBS, 40.32%) | Buy |
| Median | 56.50 (32.13%) | |
| Low | 52.00 (Barclays, 21.61%) | Buy |
| Average | 56.25 (31.55%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 43.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Jan 2026 | 58.00 (35.64%) | Buy | 44.89 |
| Citigroup | 09 Jan 2026 | 55.00 (28.62%) | Buy | 42.18 |
| UBS | 07 Jan 2026 | 60.00 (40.32%) | Buy | 44.23 |
| Barclays | 17 Dec 2025 | 52.00 (21.61%) | Buy | 44.01 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HO JUNLIN | - | 46.45 | -9,580 | -444,991 |
| MARANTZ JING L. | - | 46.45 | -4,157 | -193,093 |
| PARLAVECCHIO CARYN | - | 46.45 | -9,035 | -419,676 |
| QATANANI MO | - | 46.73 | -16,473 | -769,922 |
| Aggregate Net Quantity | -39,245 | |||
| Aggregate Net Value ($) | -1,827,681 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 46.56 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| QATANANI MO | Officer | 23 Feb 2026 | Automatic sell (-) | 8,484 | 47.01 | 398,833 |
| QATANANI MO | Officer | 17 Feb 2026 | Sell (-) | 7,989 | 46.45 | 371,089 |
| PARLAVECCHIO CARYN | Officer | 17 Feb 2026 | Sell (-) | 9,035 | 46.45 | 419,676 |
| MARANTZ JING L. | Officer | 17 Feb 2026 | Sell (-) | 4,157 | 46.45 | 193,093 |
| HO JUNLIN | Officer | 17 Feb 2026 | Sell (-) | 9,580 | 46.45 | 444,991 |
| Date | Type | Details |
|---|---|---|
| 16 Jan 2026 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Announcement | Scholar Rock Highlights 2026 Strategic Priorities |
| 05 Jan 2026 | Announcement | Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 13 Dec 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |